Risk, genomic risk, and prognosis of risk for prostate cancer metastasis and death

A recently published study in European Urology has again (partially) validated the utility of a specific type of genomic testing as a way to project risk for progressive disease in men initially diagnosed with localized prostate cancer. … READ MORE …

MRI data and genomic data are telling us different things about prostate cancer risk

A new paper just published on line in the journal PLoS One is entitled, “Association between a 17-gene genomic prostate score and a multi-parametric prostate MRI in men with low and intermediate risk prostate cancer (PCa)”. … READ MORE …

How close are we really to “precision medicine” for cancer care?

A newly published paper in the journal JCO Precision Oncology confirms what many of us may have suspected — that the practical application of somatic tissue testing to clinical decision-making was low prior to 2015 . … READ MORE …

Some “Best of ASCO” reports from UroToday

The UroToday web site has now posted a number of “Best of ASCO” reports that might be of interest to some of our readers. … READ MORE …

Can the Decipher test accurately project risk for metastasis post-surgery?

A newly published article in the Journal of Clinical Oncology suggests that the Decipher test may be able to predict risk for metastatic prostate at 10 years post-surgery. However, … READ MORE …

Genetics, genomics, targeted therapy, and the costs of care

A new paper in a new journal argues that all men diagnosed with advanced forms of prostate cancer should now, routinely, be undergoing tumor and germline DNA profiling … READ MORE …

Genomic prediction of risk for biochemical relapse post-surgery

Yet another genetic/genomic test (this one developed by Metamark Genetics) may have value in the assessment of risk for biochemical progression after first-line surgery for prostate cancer. … READ MORE …